Market capitalization | $1.85b |
Enterprise Value | $1.60b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 12.36 |
P/S ratio (TTM) P/S ratio | 14.25 |
P/B ratio (TTM) P/B ratio | 7.77 |
Revenue growth (TTM) Revenue growth | 801.96% |
Revenue (TTM) Revenue | $129.62m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:
10 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 130 130 |
802%
802%
|
|
Gross Profit | 121 121 |
853%
853%
|
|
EBITDA | -139 -139 |
24%
24%
|
EBIT (Operating Income) EBIT | -141 -141 |
24%
24%
|
Net Profit | -134 -134 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Head office | United States |
CEO | Bobak Azamian |
Employees | 244 |
Founded | 2017 |
Website | tarsusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.